Hui was also drawn to Fosun Pharma for its approach to R&D that is patient-centered and clinically driven, while also seeking technological innovation. “We seek innovation with a Chinese focus ...

is yet more proof that this is an area on the cusp of the pharmaceutical R&D mainstream. That was one of the key messages from SynBioBeta’s Synthetic Biology Biopharma Conference last month ...